Current Report Filing (8-k)
May 11 2020 - 07:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8–K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 11,
2020
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
|
Delaware |
|
001-37526 |
|
26-0389433 |
(State
or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8–K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
|
o |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
|
o |
Soliciting material
pursuant to Rule 14a–12 under the Exchange Act (17 CFR
240.14a–12) |
|
o |
Pre–commencement
communications pursuant to Rule 14d–2(b) under the
Exchange Act (17 CFR 240.14d–2(b)) |
|
o |
Pre–commencement
communications pursuant to Rule 13e–4(c) under the
Exchange Act (17 CFR 240.13e–4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value per share |
|
ZYNE |
|
The
NASDAQ Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. x
|
Item 2.02 |
Results of Operations and
Financial Condition |
On May 11, 2020, Zynerba Pharmaceuticals, Inc. (the
“Company”) issued a press release announcing its financial
results and operational highlights for the first quarter ended
March 31, 2020. A copy of this press release is furnished as
Exhibit 99.1 hereto.
The information furnished pursuant to this Item 2.02, including
Exhibit 99.1, shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of
that section, and shall not be deemed to be incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
Attached as Exhibit 99.2 is a presentation, including certain
financial information that the Company will post on its website on
May 11, 2020 and may use from time to time in presentations or
discussions with investors, analysts or other parties.
|
Item 9.01 |
Financial Statements and
Exhibits |
(d) Exhibits
* Furnished herewith
** Filed herewith
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date: May 11, 2020
| |
ZYNERBA
PHARMACEUTICALS, INC. |
| |
|
| |
By: |
/s/
Suzanne Hanlon |
| |
|
Name:
Suzanne Hanlon |
| |
|
Title:
Secretary, Vice President and General Counsel |
